Full Text View
Tabular View
No Study Results Posted
Related Studies
Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
This study is currently recruiting participants.
Study NCT00149734   Information provided by National Institute of Mental Health (NIMH)
First Received: September 6, 2005   Last Updated: March 4, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Schizophrenia
More general conditions related to this trial
Mental Disorders
Schizophrenia and Disorders with Psychotic Features
Interventions listed in this trial
Ondansetron
Pill placebo
Atypical antipsychotic drug
Additional drug interventions recognized in this trial
Antipsychotic Agents
More general drug interventions related to this trial
Anti-Anxiety Agents
Antiemetics
Antipruritics
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Dermatologic Agents
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Psychotropic Drugs
Serotonin Agents
Serotonin Antagonists
Therapeutic Uses
Tranquilizing Agents
Sponsors listed in this trial
National Institute of Mental Health (NIMH)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services